



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Ziva MESSIKA et al

Application No.: 09/445,160

Filed: March 7, 2000

For: PREPARATION OF GLYCOSYLATED TUMOR NECROSIS FACTOR

Art Unit: 1647

Examiner: J. Seharaseyon

Washington, D.C.

Atty.'s Docket: MESSIKA=1

Date: July 11, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Sir:

Transmitted herewith is a [X] Amendment [ ] \_\_\_\_\_ in the above-identified application.

[ ] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[ ] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2) MINUS	(Col. 3) HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 40	\$		x 80	\$
+ 135	\$		+ 270	\$
ADDITIONAL FEE TOTAL			TOTAL	

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [ ] First - \$ 55.00
- [ ] Second - \$ 195.00
- [ ] Third - \$ 445.00
- [ ] Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- [ ] First - \$ 110.00
- [ ] Second - \$ 390.00
- [ ] Third - \$ 890.00
- [ ] Fourth - \$ 1390.00

Month After Time Period Set

[ ] Less fees (\$\_\_\_\_\_) already paid for \_\_\_\_ month(s) extension of time on \_\_\_\_\_.

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_.


[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$\_\_\_\_\_.

[ ] A check in the amount of \$\_\_\_\_\_ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:   
Roger L. Browdy  
Registration No. 25,618

TECH CENTER 1600/2900

JUL 13 2001

RECEIVED



THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6/election  
and L  
TECH CENTER 2000-7  
JUL 13 2001  
RECEIVED

Atty. Docket: MESSIKA=1

In re Application of: ) Art Unit: 1647  
Ziva MESSIKA et al ) Examiner: J. Seharaseyon  
Appn. No.: 09/445,105 ) Washington, D.C.  
Filed: March 7, 2000 ) July 11, 2001  
For: PREPARATION OF )  
GLYCOSYLATED TUMOR )  
NECROSIS FACTOR )

**AMENDMENT**

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action of June 19, 2001,  
please amend as follows:

IN THE CLAIMS

*sub B2*

---

2. A method for preparing isolated biologically active glycosylated human tumor necrosis factor, comprising

(a) ligating DNA encoding human TNF or a physiologically active variant thereof to a replicable expression vehicle to obtain a replicable recombinant DNA comprising said DNA and said replicable expression vehicle;

(b) transforming eukaryotic cells with said replicable recombinant DNA to form transformants;